Terms: = Kidney tumors AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Diagnosis
3212 results:
1. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract] [Full Text] [Related]
2. Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.
Sammarco E; Rossetti M; Salfi A; Bonato A; Viacava P; Masi G; Galli L; Faviana P
Med Oncol; 2024 May; 41(6):150. PubMed ID: 38740647
[TBL] [Abstract] [Full Text] [Related]
3. Clinical features of patients with carcinoma soft tissue metastases as surgical indications: a retrospective cohort study.
Morinaga S; Yamamoto N; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Taniguchi Y; Asano Y; Nojima T; Tsuchiya H
BMC Cancer; 2024 May; 24(1):577. PubMed ID: 38730358
[TBL] [Abstract] [Full Text] [Related]
4. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract] [Full Text] [Related]
5. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
[TBL] [Abstract] [Full Text] [Related]
7. Timing, incidence and management of delayed bleeding after partial nephrectomy in patients at risk for recurrent, bilateral, multifocal renal tumors.
Gomella PT; Solomon J; Ahdoot M; Gurram S; Lebastchi AH; Levy E; Krishnasamy V; Kassin MT; Chang R; Wood BJ; Linehan WM; Ball MW
Urol Oncol; 2024 Jul; 42(7):222.e1-222.e7. PubMed ID: 38614921
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathologic and Molecular Characterization of Xanthomatous Giant Cell Renal Cell Carcinomas: Further Support for a Close Morphologic Spectrum to Eosinophilic Solid and Cystic Renal Cell Carcinomas.
Xu Y; Zhang X; Xia Q; Zhou Y; Wang X; Fang R; Wang Y; Tong Q; Chen J; Shi J; Fu Y; Rao Q
Am J Surg Pathol; 2024 Jun; 48(6):662-670. PubMed ID: 38595297
[TBL] [Abstract] [Full Text] [Related]
9. Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
Nusrat NB; Rehman AU; Zafar N; Muhammad S; Bajwa SI; Imtiaz S
J Pak Med Assoc; 2024 Mar; 74(3):513-518. PubMed ID: 38591289
[TBL] [Abstract] [Full Text] [Related]
10. Safety of Docetaxel in a Patient with Metastatic Castration-Resistant Prostate Cancer After kidney Transplantation: A Case Report.
Nagahisa C; Iizuka J; Kobari Y; Minoda R; Oki R; Unagami K; Yoshida K; Hirai T; Omoto K; Shimizu T; Ishida H; Takagi T
Transplant Proc; 2024 Apr; 56(3):729-733. PubMed ID: 38548511
[TBL] [Abstract] [Full Text] [Related]
11. National clinical and financial outcomes associated with acute kidney injury following esophagectomy for cancer.
Ng AP; Chervu N; Branche C; Bakhtiyar SS; Marzban M; Toste PA; Benharash P
PLoS One; 2024; 19(3):e0300876. PubMed ID: 38547215
[TBL] [Abstract] [Full Text] [Related]
12. Characteristics of high frame frequency contrast-enhanced ultrasound in renal tumors.
Zhang W; Wang J; Chen L
BMC Med Imaging; 2024 Mar; 24(1):71. PubMed ID: 38528467
[TBL] [Abstract] [Full Text] [Related]
13. Recurrent bladder leiomyoma: a case report.
Yogeeta F; Malik Z; Rauf SA; Devi M; Tooba F; Jamalvi SA; Rashid M; Erum H
J Med Case Rep; 2024 Mar; 18(1):173. PubMed ID: 38515215
[TBL] [Abstract] [Full Text] [Related]
14. Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study.
Baard J; Cormio L; Dasgupta R; Maruzzi D; Rais-Bahrami S; Serrano A; Geavlete B; Giannakopoulos S; de la Rosette J; Laguna P
World J Urol; 2024 Mar; 42(1):177. PubMed ID: 38507109
[TBL] [Abstract] [Full Text] [Related]
15. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
[TBL] [Abstract] [Full Text] [Related]
16. Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study.
Munshi L; Dumas G; Rochwerg B; Shoukat F; Detsky M; Fergusson DA; Ferreyro BL; Heffernan P; Herridge M; Magder S; Minden M; Patel R; Qureshi S; Schimmer A; Thyagu S; Wang HT; Mehta S
Intensive Care Med; 2024 Apr; 50(4):561-572. PubMed ID: 38466402
[TBL] [Abstract] [Full Text] [Related]
17. A Rare Case of Donor-Derived Renal Cell Carcinoma in a kidney Transplant Recipient.
Sebastian W; Omar KO; Anees R; Nagaraju S; Chaitanya M
Am J Case Rep; 2024 Mar; 25():e941214. PubMed ID: 38442088
[TBL] [Abstract] [Full Text] [Related]
18. Clinical features, laboratory findings and treatment of juxtaglomerular cell tumors: a systemic review.
Dong H; Zuo Y; An X; Li H; Zheng Z; Chen Y; Zou Y; Jiang X
Hypertens Res; 2024 May; 47(5):1380-1390. PubMed ID: 38438720
[TBL] [Abstract] [Full Text] [Related]
19. OPTN/SRTR 2022 Annual Data Report: Liver.
Kwong AJ; Kim WR; Lake JR; Schladt DP; Schnellinger EM; Gauntt K; McDermott M; Weiss S; Handarova DK; Snyder JJ; Israni AK
Am J Transplant; 2024 Feb; 24(2S1):S176-S265. PubMed ID: 38431359
[TBL] [Abstract] [Full Text] [Related]
20. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract] [Full Text] [Related]
[Next]
